Prospective, randomized, open label phase II study to assess efficacy and safety of Macugen® (pegaptanib 0.3 mg intravitreal injections) plus panretinal photocoagulation (PRP) and PRP (monotherapy) in the treatment of patients with high risk proliferative diabetic retinopathy [more info]
Prospective, randomized, multicenter, open label phase II study to access efficacy and safety of Lucentis® monotherapy (ranibizumab 0.5 mg intravitreal injections) compared with Lucentis® plus panretinal photocoagulation (PRP) and PRP (monotherapy) in the treatment of patients with high risk proliferative diabetic retinopathy [more info]
Epidemiological study of the prevalence of Age-Related Macular Degeneration in Portugal [more info]